Dr Andrea Van Elsas
CSO, Aduro Biotech Europe
Andrea van Elsas became Chief Scientific Officer of Aduro Biotech Europe in November 2015. He completed his thesis on melanoma antigens and their use in cancer immunotherapy in 1996 (Leiden University Medical Center). A KWF (Dutch Cancer Society) fellowship allowed him to study manipulation of T cell co-stimulation using antibodies blocking CTLA-4 for the treatment of cancer at the University of California in Berkeley, CA. He is a co-inventor on the original patents that formed the basis for the development of ipilimumab. After his academic career, Andrea joined Organon where he was involved in the foundation of the Organon Research Center in Cambridge, MA. Between 2007 – 2009, he served in Cambridge as Head of Oncology Biologics Discovery for Organon and POC team leader for Schering-Plough’s Immune Oncology portfolio. He managed various discovery alliances with biotech and academia in the field of Oncology and he is a co-founder of BioNovion.